Currency In USD
| Previous Close | 14.82 |
| Open | 14.51 |
| Day High | 14.6 |
| Day Low | 13.11 |
| 52-Week High | 20.22 |
| 52-Week Low | 9.82 |
| Volume | 1.58M |
| Average Volume | 1.96M |
| Market Cap | 1.94B |
| PE | -40.04 |
| EPS | -0.34 |
| Moving Average 50 Days | 14.17 |
| Moving Average 200 Days | 14.49 |
| Change | -1.2 |
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
GlobeNewswire Inc.
Mar 10, 2026 8:05 PM GMT
Conference call and webcast to be held at 4:30 p.m. ETNEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nal
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
GlobeNewswire Inc.
Mar 09, 2026 11:30 AM GMT
The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter of 2026, with the second pivotal trial expected to in
Trevi Therapeutics to Participate in Upcoming March Conferences
GlobeNewswire Inc.
Mar 02, 2026 12:30 PM GMT
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in pati